Earnings Call Intelligence Subscribe
Home › Call Sheets › TMO › Q1'26
Call sheet · Q1'26

Thermo Fisher Scientific (TMO)

Q1'26 earnings call · held April 23, 2026 · compared with the Q4'25 call · management-credibility review
9/12
Disclosure score
1 medium, 5 low flags
Financial quality
Bottom line
The sleeper story is clinical research quietly becoming TMO's growth engine with strong authorizations and revenue acceleration while everyone obsesses over instrument recovery. Marc's customer anecdotes about trusted partner status aren't just narrative - they're translating into measurable share gains in the highest-margin services. The binding constraint right now isn't demand but their own capacity in sterile fill-finish and clinical capabilities, which the Clario acquisition directly addresses. Most revealing quote: Jim Meyer saying the $0.13 operational beat shows 'continued active management and power of PPI Business System' - this execution engine is their real moat in a choppy macro. My view changes if Q2 organic growth comes in below that 3% guide or if they start hedging on the Clario revenue synergies at the May 20 Analyst Day.

The 30-second version

  • SLEEPER STORY: Clinical Research is now quietly the real growth engine while everyone obsesses over instruments
  • Beat was 100% operational excellence, not market recovery - that's the real bullish signal
  • They're pre-building inflation cushions while talking about 'retiring risk' - defensive positioning suggests uncertainty ahead

What changed this quarter

MetricQ4'25Q1'26Change
Total Revenue$12.21B (+7% YoY Q4)$11.01B (+6% YoY Q1)Slight deceleration but solid beat vs guidance
Adjusted EPS$6.57 (+8% YoY Q4)$5.44 (+6% YoY Q1)200bps growth deceleration, beat guidance by $0.14
Adjusted Operating Margin23.6% Q421.8% Q1180bps sequential decline, 10bps YoY decline
Organic Growth3% Q41% Q1200bps deceleration, impacted by selling days
Free Cash Flow$6.34B full year 2025$830M Q1Solid quarterly performance
Life Sciences Solutions Revenue4% organic Q41% organic Q1300bps organic growth deceleration
Analytical Instruments RevenueFlat organic Q4-2% organic Q1Turned negative, macro headwinds persist
LPBS Segment Revenue5% organic Q44% organic Q1100bps deceleration but still strongest segment
Pharma & Biotech End MarketHigh single-digit Q4Mid-single-digit Q1Growth normalization from strong Q4
Academic & GovernmentLow single-digit decline Q4/yearLow single-digit decline Q1Persistent weakness, no improvement

Accountability tracked

8 new promises made4 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full TMO Q1'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.